Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study

Publikation: Bidrag til tidsskriftLetterForskningpeer review

DOI

  1. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cellulitis in chronic oedema of the lower leg: an international cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Copper release from metals may mask positive nickel spot test results

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Guidelines for diagnosis, prevention, and treatment of hand eczema

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind186
Udgave nummer4
Sider (fra-til)746-748
Antal sider3
ISSN0007-0963
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

Funding Information:
Conflicts of interest: with no relation to the current work, A.E. has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galápagos NV, Sun Pharmaceutical Industries Limited, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, Dermavant Sciences, Inc., UCB, Mylan, Bristol Myers Squibb and Janssen. J.P.T. has attended advisory boards for Eli Lilly, Almirall, Arena Pharmaceuticals, Inc., Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi Genzyme, been an investigator for LEO Pharma, Sanofi Genzyme, Eli Lilly, AbbVie and Pfizer, and received speaker honoraria from LEO Pharma, Pfizer, Almirall, AbbVie, Eli Lilly, Regeneron and Sanofi‐Genzyme. C.V. has been a speaker, investigator and served at advisory boards for and received research grants from Novartis. S.F.T. has been a speaker, investigator, served on advisory boards and received research support from Novartis. Z.A. and J.A.S. declare they have no conflicts of interest.

ID: 75487481